NR4A3 (9q22.33) Rearrangement, FISH, Tissue
Use
Identifying NR4A3 gene rearrangements is useful for supporting the diagnosis of extraskeletal myxoid chondrosarcoma or acinic cell carcinoma when used in conjunction with an anatomic pathology consultation. Rearrangement of the NR4A3 gene region may be involved with up to 4 partner genes as a pathway to EMC. Fluorescence in situ hybridization analysis allows for the detection of rearrangement of the NR4A3 gene region.
Special Instructions
A pathology report is required for testing. Submit a formalin-fixed, paraffin-embedded (FFPE) tumor tissue block. Blocks prepared with alternative fixation methods will be attempted but are less favorable for successful results by FISH testing. Paraffin-embedded specimens can be from any anatomic location. Bone specimens that have been decalcified will be attempted for testing, but the success rate is approximately 50%.
Limitations
This test is not approved by the US Food and Drug Administration and should be used as an adjunct to existing clinical and pathologic information. It does not rule out other chromosome abnormalities. Fixatives other than formalin may not be successful, and decalcified tissue has a lower success rate. A negative result does not exclude the diagnosis of extraskeletal myxoid chondrosarcoma or acinic cell carcinoma of the salivary gland.
New York Approved
Methodology
Chromosomal / Cytogenetics (FISH)
Biomarkers
LOINC Codes
- 21796-8
- 50397-9
- 69965-2
- 62356-1
- 31208-2
- 80398-1
- 85069-3
- 48767-8
- 62364-5
- 18771-6
- 42349-1
Result Turnaround Time
7-10 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Submit a formalin-fixed, paraffin-embedded (FFPE) tumor tissue block.
Storage Instructions
Ambient (preferred), Refrigerated also acceptable.
Causes for Rejection
Non-formalin fixed specimens will not be rejected, but success rate is lower.